SmithKline Beecham has agreed to market in Europe, Australia and New Zealand a testosterone transdermal patch developed and clinically tested by TheraTech, 417 Wakara Way.

Under the agreement, SmithKline acquires the exclusive rights to market and distribute the patches, which are intended for the treatment of male hypogonadism, a syndrome when the body produces insufficient amounts of the male hormone, testosterone.The patch employs TheraTech's proprietary permeation en-hanc-ers, anti-irritant and liquid reservoir system design.

Last year, the two companies signed a marketing and distribution agreement for the patches in the United States and Canada.

TheraTech made a new drug application to the Food and Drug Administration seeking approval of the patch last September. If approved, the patch will be marketed in the United States under the name Androderm.